Join to View Full Profile
1831 N Belcher RdSte D2Clearwater, FL 33765
Phone+1 727-734-6631
Fax+1 727-736-0548
Are you Dr. Levin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Levin, MD is a rheumatologist in Clearwater, Florida. He is currently licensed to practice medicine in Florida and Pennsylvania.
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalFellowship, Rheumatology, 1987 - 1989- Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1984 - 1987
- Drexel University College of MedicineClass of 1984
MCP-Hahnemann College of MedicineClass of 1984
Certifications & Licensure
FL State Medical License 1989 - 2027
PA State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Publications & Presentations
PubMed
- 1 citationsA Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-...Stanley Cohen, Jean S Beebe, Vishala Chindalore, Shunjie Guan, Mina Hassan-Zahraee
Arthritis Research & Therapy. 2024-06-06 - 9 citationsSecukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study.Tien Nguyen, Melvin Churchill, Robert Levin, Guillermo Valenzuela, Joseph F Merola
The Journal of Rheumatology. 2022-08-01 - 6 citationsClinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of ...Vibeke Strand, Stanley B Cohen, Jeffrey R Curtis, Lixia Zhang, Alan J Kivitz
Expert Review of Molecular Diagnostics. 2022-01-01
Press Mentions
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug ClassJune 24th, 2021- The ‘Great American Switching Experiment’: Cyltezo Debut Ushers in Interchangeable EraJuly 25th, 2023
